Disease models

Streptozotocin-Induced Diabetic Retinopathy

The Streptozotocin (STZ)-induced Diabetic Retinopathy model has been widely used in research for decades, with the first publications on STZ-induced diabetes appearing as early as the 1960s. This model is based on the ability of STZ to selectively destroy pancreatic β-cells, leading to chronic hyperglycemia and subsequent retinal complications. Over time, animals develop progressive retinal changes that mimic early-stage human diabetic retinopathy, including vascular leakage, pericyte loss, and inflammation. The severity of retinal pathology depends on various factors such as the STZ dose, animal species, and duration of diabetes. Due to its reproducibility and relevance to human disease, the STZ-induced diabetic retinopathy model remains a cornerstone for studying diabetes-related retinal dysfunction and evaluating potential therapeutic strategies.

To track disease progression and evaluate treatment effects, Experimentica uses in vivo imaging and functional assessments for long-term monitoring of the STZ-induced diabetic retinopathy model. Spectral-domain optical coherence tomography (SD-OCT) captures high-resolution images of the retinal layers, allowing assessment of retinal thinning. Pattern electroretinography (pERG) evaluates retinal ganglion cell (RGC) function, while optomotor response test assesses visual acuity and contrast sensitivity.

Technical details

Animal species

Mouse and rat

Method of induction

Intraperitoneal injection of STZ

Follow-up period

Up to 16 weeks

Readouts

– Glucose measurements
– Retinal layer thickness measurements (SD-OCT),
– Functional measurements (ERG, VEP),
– Behavioral assessment (visual acuity and contrast sensitivity)
– Immunohistochemistry